Featuring an interview with Dr Alexander E Drilon, including the following topics:

• Overview of targetable biomarkers in lung cancer (0:00)
• Biomarker testing for genomic alterations in lung cancer (5:24)
• Overview of ROS1 alterations in lung cancer (13:44)
• Efficacy data with ROS1 inhibitors for lung cancer (17:02)
• Safety data with ROS1 inhibitors for lung cancer (21:15)
• Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)
• Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)
• Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

NCPD information and select publications